Siegel R.L. Miller K.D. Fuchs H.E. et al.

Cancer statistics, 2022.

CA Cancer J Clin. 72: 7-33

Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria | J Urol.

() ()Barocas D.A. Boorjian S.A. Alvarez R.D. et al.

Microhematuria: AUA/SUFU Guideline.

J Urol. 204: 778-786Chang S.S. Boorjian S.A. Chou R. et al.

Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline.

J Urol. 196: 1021-1029

Optimal Trial Design for Studying Urinary Markers ...: Find It! Options.

() ()Woldu S.L. Souter L. Boorjian S.A. et al.

Urinary-based tumor markers enhance microhematuria risk stratification according to baseline bladder cancer prevalence.

Urol Oncol Semin Orig Investig. 39: 787.e1-787.e7Miyanaga N. Akaza H. Tsukamoto T. et al.

Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria.

Int J Urol. 6: 173-177Wang Z. Que H. Suo C. et al.

Evaluation of the NMP22 BladderChek test for detecting bladder cancer: a systematic review and meta-analysis.

Oncotarget. 8: 100648-100656Grossman H.B. Messing E. Soloway M. et al.

Detection of Bladder Cancer Using a Point-of-Care Proteomic Assay.

JAMA. 293: 810-816Chou R. Gore J.L. Buckley D. et al.

Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis.

Ann Intern Med. 163: 922-931Lotan Y. Elias K. Svatek R.S. et al.

Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker.

J Urol. 182 (): 52-57Huang Y.L. Chen J. Yan W. et al.

Diagnostic accuracy of cytokeratin-19 fragment (CYFRA 21-1) for bladder cancer: a systematic review and meta-analysis.

Tumour Biol J Int Soc Oncodevelopmental Biol Med. 36: 3137-3145Schmitz-Dräger B.J. Droller M. Lokeshwar V.B. et al.

Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus.

Urol Int. 94: 1-24

UroVysion FISH test for detecting urothelial cancers: Meta-analysis of diagnostic accuracy and comparison with urinary cytology testing.

Urol Oncol Semin Orig Investig. 26: 646-651Maas M. Bedke J. Stenzl A. et al.

Can urinary biomarkers replace cystoscopy?.

World J Urol. 37: 1741-1749O’Sullivan P. Sharples K. Dalphin M. et al.

A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.

J Urol. 188: 741-747Raman J.D. Kavalieris L. Konety B. et al.

The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma.

J Urol. 206: 1380-1389van Valenberg F.J.P. Hiar A.M. Wallace E. et al.

Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria.

Eur Urol Oncol. 4: 93-101Robertson A.G. Kim J. Al-Ahmadie H. et al.

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Cell. 171 (): 540-556Casadio V. Calistri D. Tebaldi M. et al.

Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data.

Urol Oncol. 31: 1744-1750Tomlinson D.C. Baldo O. Harnden P. et al.

FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.

J Pathol. 213: 91-98Allory Y. Beukers W. Sagrera A. et al.

Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.

Eur Urol. 65: 360-366Piatti P. Chew Y.C. Suwoto M. et al.

Clinical evaluation of Bladder CARE, a new epigenetic test for bladder cancer detection in urine samples.

Clin Epigenetics. 13: 84Hentschel A.E. Beijert I.J. Bosschieter J. et al.

Bladder cancer detection in urine using DNA methylation markers: a technical and prospective preclinical validation.

Clin Epigenetics. 14: 19

Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma - PubMed.

() ()

Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker - PubMed.

() ()

Urinary carbonic anhydrase IX splicing messenger RNA variants in urogenital cancers - PubMed.

() ()

Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer - PubMed.

() ()Ku J.H. Godoy G. Amiel G.E. et al.

Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review.

BJU Int. 110: 630-636Shariat S.F. Casella R. Khoddami S.M. et al.

Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer.

J Urol. 171: 626-630Horstmann M. Bontrup H. Hennenlotter J. et al.

Clinical experience with survivin as a biomarker for urothelial bladder cancer.

World J Urol. 28: 399-404

A urinary microRNA signature can predict the presence of bladder urothelial carcinoma in patients undergoing surveillance | British Journal of Cancer.

() ()Kutwin P. Konecki T. Borkowska E.M. et al.

Urine miRNA as a potential biomarker for bladder cancer detection – a meta-analysis.

Cent Eur J Urol. 71: 177-185Roperch J.P. Grandchamp B. Desgrandchamps F. et al.

Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.

BMC Cancer. 16: 704Dahmcke C.M. Steven K.E. Larsen L.K. et al.

A Prospective Blinded Evaluation of Urine-DNA Testing for Detection of Urothelial Bladder Carcinoma in Patients with Gross Hematuria.

Eur Urol. 70: 916-919

Evaluation of an Epigenetic Profile for the Detection of Bladder Cancer in Patients with Hematuria | J Urol.

() ()Grossman H.B. Soloway M. Messing E. et al.

Surveillance for Recurrent Bladder Cancer Using a Point-of-Care Proteomic Assay.

JAMA. 295: 299-305Lotan Y. OʼSullivan P. Raman J.D. et al.

Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.

Urol Oncol Semin Orig Investig. 35: 531.e15-531.e22Raitanen M.P. FinnBladder Group

The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.

World J Urol. 26: 45-50Guo A. Wang X. Gao L. et al.

Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: A meta-analysis.

Can Urol Assoc J. 8: E347-E352

Urine Sediment Smears as a Diagnostic Procedure in Cancers of the Urinary Tract.

() ()Yafi F.A. Brimo F. Auger M. et al.

Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer.

Urol Oncol Semin Orig Investig. 32: 27.e1-27.e6Gudjónsson S. Isfoss B.L. Hansson K. et al.

The Value of the UroVysion® Assay for Surveillance of Non–Muscle-Invasive Bladder Cancer.

Eur Urol. 54: 402-408Davis N. Shtabsky A. Lew S. et al.

A Novel Urine-Based Assay for Bladder Cancer Diagnosis: Multi-Institutional Validation Study.

Eur Urol Focus. 4: 388-394

Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study | J Urol.

() ()Yun S.J. Jeong P. Kim W.T. et al.

Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer.

Int J Oncol. 41: 1871-1878Critelli R. Fasanelli F. Oderda M. et al.

Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.

Oncotarget. 7: 67435-67448Wasserstrom A. Frumkin D. Dotan Z. et al.

Mp13-15 molecular urine cytology – bladder epicheck is a novel molecular diagnostic tool for monitoring of bladder cancer patients.

J Urol. 195: e140Su S.F. de Castro Abreu A.L. Chihara Y. et al.

A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence.

Clin Cancer Res. 20: 1978-1989Beukers W. van der Keur K.A. Kandimalla R. et al.

FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.

J Urol. 197: 1410-1418Mengual L. Marín-Aguilera M. Ribal M.J. et al.

Clinical Utility of Fluorescent in situ Hybridization for the Surveillance of Bladder Cancer Patients Treated with Bacillus Calmette-Guérin Therapy.

Eur Urol. 52: 752-759Kipp B.R. Karnes R.J. Brankley S.M. et al.

Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization.

J Urol. 173: 401-404Kamat A.M. Dickstein R.J. Messetti F. et al.

Use of Fluorescence In Situ Hybridization to Predict Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer: Results of a Prospective Trial.

J Urol. 187: 862-867Lotan Y. Inman B.A. Davis L.G. et al.

Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.

J Urol. 202: 920-926Odisho A.Y. Berry A.B. Ahmad A.E. et al.

Reflex ImmunoCyt Testing for the Diagnosis of Bladder Cancer in Patients with Atypical Urine Cytology.

Eur Urol. 63: 936-940

Prospective Evaluation of the Clinical Usefulness of Reflex Fluorescence In Situ Hybridization Assay in Patients With Atypical Cytology for the Detection of Urothelial Carcinoma of the Bladder | J Urol.

() ()Schlomer B.J. Ho R. Sagalowsky A. et al.

Prospective Validation of the Clinical Usefulness of Reflex Fluorescence In Situ Hybridization Assay in Patients With Atypical Cytology for the Detection of Urothelial Carcinoma of the Bladder.

J Urol. 183: 62-67Badrinath K. Neal S. Andrew K.K. et al.

Yair Lotan. Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy.

Eur Urol. 76: 238-243Zuiverloon T.C.M. Tjin S.S. Busstra M. et al.

Optimization of Nonmuscle Invasive Bladder Cancer Recurrence Detection Using a Urine Based FGFR3 Mutation Assay.

J Urol. 186: 707-712Christensen E. Birkenkamp-Demtröder K. Nordentoft I. et al.

Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.

Eur Urol. 71: 961-969Kamat A.M. Briggman J. Urbauer D.L. et al.

Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin.

Eur Urol. 69: 197-200Rosser C.J. Chang M. Dai Y. et al.

Urinary Protein Biomarker Panel for the Detection of Recurrent Bladder Cancer.

Cancer Epidemiol Biomarkers Prev. 23: 1340-1345

Use of a Multiplexed Molecular Biomarker Test Cxbladder.

in: Real World Decision making to provide clinical utility using a randomized Design. clinicaltrials.gov, () ()